Eyenable® intraocular lenses
Eyenable® intraocular lenses
Hydrophobic acrylic monofocal IOL
High quality, high performance
Eyenable acrylate monofocal IOLs offer proven high optical and biological performance
- Single focus intraocular lenses
- Clear vision at one point of focus
- High optical performance
Proven in millions of successful procedures
Hydrophobic acrylate intraocular lenses
Eyenable IOLs are made of hydrophobic acrylate material containing ultraviolet absorber.
This acrylic copolymer is a safe biomaterial with excellent optical properties.
Proven in millions of successful procedures
Hydrophobic acrylate intraocular lenses
Eyenable IOLs are made of hydrophobic acrylate material containing ultraviolet absorber.
This acrylic copolymer is a safe biomaterial with excellent optical properties.
Specifications
Optical type
Asymmetric biconvex optical surface
Material
Acrylic copolymer
Intraocular lens power range
+10.0 D to +30.0 D, every 0.5 D interval
Refractive index
1.55
Core diameter
6.0 mm
Total diameter
13.0 mm
Loop angle
0°


Products
Visionary clarity
Next-generation IOL made from
our globally patented cross-linked Polyisobutylene (xPIB)
Eyedeal is committed to helping cataract patients around the world regain their sight

Eyenable foldable intraocular lenses are made of conventional hydrophobic acrylate materials. Eyedeal has mastered the R&D and production of the whole process, from material synthesis and product design to process manufacturing, to provide patients with affordable good performance, high-quality IOLs.
Next-generation xPIB IOL
Processed by cross-linked polyisobutylene (xPIB) material.
The Eyedeal series are the world’s latest generation of intraocular lenses. They are made of cross-linked polyisobutylene (xPIB) material. Global experts believe that cross-linked polyisobutylene intraocular lenses have better biocompatibility and stability, as well as excellent optical and mechanical properties. They require only a micro-incision while achieving a large optical surface, and reduce glare (positive and negative dysphotopsia) to provide patients with better intraocular lenses over the long-term.
Eyedeal has a global patent for cross-linked polyisobutylen (xPIB) material technology. This ends China’s reliance on importing high-end medical polymer materials and contributes to the goal of made-in-China products leading the world.


Eyedeal – paying attention to young people’s eye health
Orthokeratology (OK lens) is a rigid contact lens designed with rigid oxygen-permeable materials, which can reverse myopia or slow down the progression of myopia to a certain extent by temporarily changing the corneal shape.
In the “Guidelines for the Prevention and Treatment of Myopia” issued by the National Health and Medical Commission in 2018, orthokeratology lenses are listed as one of the effective methods for the prevention and control of myopia.
Eyedeal develops and designs a new orthokeratology lens
We have synthesized a highly biocompatible material with high oxygen permeability and low wetting angle. Its unique segmented optical design is more in line with the characteristics of the Asian eye and is more comfortable. The new precision machining process produces higher quality products.
Eyedeal ICL – see the wonderful world
Globally, phakic intraocular lenses (Phakic ICL) are widely recognized as an effective option for translating high refractive errors.
Eyedeal uses a new generation of ICLs designed and developed with globally patented cross linked polyisobutylene polymer materials, which have excellent performance and reduce the occurrence of adverse reactions, mainly helping customers with high myopia.


New treatment options for glaucoma patients
Glaucoma is the second leading cause of blindness in the world after cataracts, but the first irreversible cause of blindness.
Treatment of glaucoma
Glaucoma is mainly treated by reducing intraocular pressure to avoid optic nerve damage, or preventing optic nerve damage from continuing to develop.
Minimally invasive glaucoma surgery (MIGS) and glaucoma drainage tube implantation is a relatively simple procedure with few complications with low impact on patient quality of life. It is one of the best treatments for glaucoma.
Eyedeal pioneers and innovates in the field of glaucoma drainage tubes
Eyedeal’s team of ophthalmologists relies on unique material advantages and rich industry experience to develop the first domestic glaucoma drainage tube with independent intellectual property rights. With better biological safety and biological stability, it solves the problems of current drainage tube products
Global patent, broad platform
Eyedeal has cooperated with Dr Leonard Pinchuk, Member of the American Academy of Engineering and recipient of the 2019 Russ Prize, to develop a new medical material – cross-linked polyisobutylene (xPIB).
Crosslinked polyisobutylene (crosslinked polyisobutylene-[CH2-C(CH3)2]n, xPIB) is synthesized from branched olefins and vinyl comonomers through high-temperature chemical cross-linking, which has been proven to have excellent clinical efficacy and biocompatibility.
Advantages of crosslinked polyisobutylene
Homogeneous homopolymer / No hydrolyzable groups / No degradation by-products / Alternating quaternary carbons in the main chain
Eyedeal has independent intellectual property rights and global patents for crosslinked polyisobutylene materials. We focus on other potential application scenarios and explore the infinite possibilities of crosslinked polyisobutylene.
As one of the few medical implantable materials with source innovation and complete intellectual property rights in China, cross-linked polyolefins also have very high value in orthopedics, neurosurgery, thoracic surgery and other fields.
Eyedeal regards R&D and innovation as fundamental. Our scientists and engineers focus on unmet clinical needs, actively expand scientific boundaries, develop new medical materials, and develop more extensive and in-depth product lines.

History and milestones
Our history and milestones



2025
September – xPIB IOL is approved by NMPA
September – xPIB was selected for the National Biomedical Materials Innovation Task List
April – Clinical research results on the xPIB IOL were released globally at ASCRS 2025
January – Eyedeal was approved to establish the Shaanxi Academician Workstation
2024
November – Research results of the xPIB IOL was presented at he 17th Joint Meeting of China-Japan-Korea Ophthalmologists
November – Eyedeal was awarded the “Bright Merit Award” by the China Health Express Foundation
November – Clinical trial of hydrophobic acrylic toric IOL was completed in China
July – Research results of the xPIB IOL was presented at the 36th International Congress of Germen Ophthalmic Surgery
2023
December –Clinical trial of the xPIB IOL was completed in China
December – Eyedeal was approved as Shaanxi Demonstration Base for Talent Introduction
August – The xPIB IOL was selected as one of the China’s Top 100 Most Innovative Medical Devices of 2023
April –Eyedeal successfully completed its Series B financing round.
March – Eyedeal was approved to establish the Shaanxi Provincial Engineering Research Center
2022
October – Eyenable® IOL received approval for market launch in China
August – Clinical trial of Eyenable® Toric IOL was initiated in China
May – National Key R&D Program led by Eyedeal successfully passed the final acceptance
March – Eyedeal was approved to establish the Xi’an Engineering Research Center


2021
April – Obtained CE Marking for the Eyenable® IOL.
August – Initiated clinical trial for Eyedeal®, a next generation IOL.
2020
May – Obtained “Special Review Procedure for Innovative Medical Devices” status from the NMPA.
2019
January – Obtained “Academician Expert Workstation” status.
October – Initiated clinical trial for Eyenable® IOL.
November – Established “Postdoctoral Innovation Base”.
2017
July – Received prestige grant of “National Key R&D Program”.
2015
January – Registered and established Xi’an Eyedeal Medical Technology Co., Ltd.
June – Completed a GMP facility with full function of R&D, manufacturing and operation.














